VK2735 Supports Reduced Frequency Weight Maintenance Dosing

Company Viking Therapeutics Event Type Clinical Trial Data Readout Modality Peptide Dual Agonist Asset VK2735 Target GLP-1 / GIP receptors Disease Area Obesity Summary Viking reported that participants switching from weekly VK2735 induction to every other week dosing maintained an average 90 percent of prior…